Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 2/3 3Phase 3 2Phase NA 1Phase 1/2 1

Status

Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 23Carboplatin 23pembrolizumab 21Paclitaxel 20Gemcitabine 19Specimen Handling 16Doxorubicin 15Dexamethasone 15Radiotherapy 14Nivolumab 14Drug Therapy 14Cyclophosphamide 14Bevacizumab 14atezolizumab 13Oxaliplatin 13Vincristine 11Radiation 11Prednisone 11Pemetrexed 11Cytarabine 11venetoclax 10Docetaxel 10Capecitabine 10Trastuzumab 9Rituximab 9Temozolomide 8Platinum 8Ipilimumab 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × disitamab vedotin × 1 year × Clear all
NCT07608224 2026-05-27

HOPE-07-MIBC

West China Hospital

Phase 2/3 Not yet recruiting
240 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07366840 2026-01-26

BRIGHT

Fudan University

Phase 2/3 Not yet recruiting
268 enrolled
Breast

Breast Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

RemeGen Co., Ltd.

Phase 2/3 Active not recruiting
201 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡